Endorsing our findings, additional data from publicly available databases were extracted, demonstrating a consistent decrease in AKR1D1 expression in patients with advanced NAFLD, compared to mild NAFLD (Supplementary Fig. 1) (GEO accession GSE49541; [31,32]). Here, AKR1D1 is linked to metabolic dysfunction-associated steatotic liver disease.